The immunosuppressive tumor microenvironment in glioblastoma - Takeaways - MDSpire

The immunosuppressive tumor microenvironment in glioblastoma

  • By

  • Jing Yang

  • Jie Li

  • Ming Jin

  • Yongping Lu

  • Li Zhang

  • July 2, 2026

  • 0 min

Share

  • 1

    Glioblastoma (GBM) is a highly aggressive brain tumor with poor outcomes despite treatment efforts including surgery and chemotherapy.

  • 2

    The immunosuppressive microenvironment in GBM is characterized by immune exclusion, defective antigen presentation, and myeloid cell dominance.

  • 3

    Tumor-associated macrophages and microglia play a crucial role in establishing a suppressive immune network that hinders antitumor immunity.

  • 4

    Key molecular pathways, such as TGF-β/SMAD and IL-10/STAT3, contribute to immune evasion by suppressing T-cell activation and promoting myeloid tolerance.

  • 5

    Understanding the mechanisms of immune suppression in GBM is essential for developing effective combination therapies to enhance treatment responses.

Original Source(s)

The immunosuppressive tumor microenvironment in glioblastoma

  • by Jing Yang, Jie Li, Ming Jin, Yongping Lu, Li Zhang

  • July 2, 2026

Related Content

Factors associated with relapse/progression in pediatric trunk and extremity rhabdomyosarcoma

ASCO26: Michael Hassett, MD, MPH, eSyM

Dr. Michael Hassett of Dana-Farber Cancer Institute shared new findings showing deployment of eSyM, an ePRO-based, EHR-integrated symptom management program, was associated with statistically significant and potentially meaningful improvements in overall survival. Strategies to improve adoption of ePRO-based symptom management may be warranted.

  • July 1, 2026

  • 1 min
First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial